drugset / Trial / NCT03958396

Remifentanil in Children With Obstructive Sleep Apnea

NCT03958396

Phase 0 Completed 30 enrolled Washington University School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This investigation tested the hypothesis that children with obstructive sleep apnea have an increased pharmacodynamic sensitivity to the miotic and respiratory depressant effects of the prototypic μ-opioid agonist remifentanil.

Timeline

Start
2015-09-01
Primary completion
2017-10-31
Completion
2017-10-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Remifentanil Small molecule 0.05 ug/kg
Comparator Remifentanil Small molecule 0.1 ug/kg
Comparator Remifentanil Small molecule 0.15 ug/kg
Comparator Remifentanil Small molecule 0.2 ug/kg